Opthea
BioTech/Drugs - South Yarra, Victoria, AU
Opthea Details
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate, sozinibercept, is being evaluated in two pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents. To learn more, visit our website and follow us on X and LinkedIn. Enquiries can be directed to: info@opthea.com
Opthea Technologies
Email Providers
Outlook
CMS
WordPress.org
Tag Management
Google Tag Manager
Hosting
Amazon AWS
Online Video Platforms
Vimeo
Other
Mobile Friendly